{"product_id":"hapvida-swot-analysis","title":"Hapvida SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eHapvida’s integrated healthcare model combines scale, strong regional brand recognition, and cost-efficient vertically integrated services, yet it faces regulatory pressures and margin risks from rising medical costs; discover how these forces shape growth prospects and competitive resilience. Purchase the full SWOT analysis to access a research-backed, editable report and Excel matrix—ideal for investors, strategists, and advisors seeking actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertically Integrated Business Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHapvida runs ~400 own hospitals and 2,400 clinics\/diagnostic units, giving tight control of the patient journey and costs and cutting third-party fees; in 2024 owned-asset revenue represented ~62% of total service income. This vertical integration limits margin leakage to external providers and supports lower pricing power versus peers. By end-2025 the model remains the main enabler of Hapvida’s market-competitive pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Share and Scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing its consolidation through the 2020-24 acquisitions, Hapvida (Grupo HapVida S.A., B3: HAPV3) became one of Latin America’s largest healthcare operators with ~14 million beneficiaries by end-2024, yielding strong economies of scale. That scale gives Hapvida material bargaining power—reported procurement savings helped cut cost per beneficiary by ~6% in 2023–24—and supports wider actuarial risk pooling across its health and dental portfolios, lowering claim volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Leadership in North and Northeast\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHapvida holds a dominant footprint in Brazil’s North and Northeast, operating over 60% of its 1,200+ owned clinics and hospitals there as of FY2024, giving it deep local networks and patient flow.\u003c\/p\u003e\n\u003cp\u003eThese regions face less insurer concentration than the South\/Southeast, so Hapvida’s regional mix delivered ~55% of consolidated revenue and steadier margins in 2024.\u003c\/p\u003e\n\u003cp\u003eThe physical infrastructure — large hospital park and local distribution — creates a high-cost barrier for entrants, protecting market share and cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocus on Affordable Healthcare Tiers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHapvida delivers affordable, private healthcare tailored to Brazil’s emerging middle class and cost-sensitive corporates, serving about 7.3 million beneficiaries after 2022 M\u0026amp;A (2024 est.).\u003c\/p\u003e\n\u003cp\u003eThe company sustains low-cost plans with a vertically integrated network and lean ops, yielding a 2024 adjusted EBITDA margin near 18% and supporting profitable scale versus public-system gaps.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e7.3M beneficiaries (post-merger, 2024 est.)\u003c\/li\u003e\n\u003cli\u003e~18% adjusted EBITDA margin (2024)\u003c\/li\u003e\n\u003cli\u003eVertical integration: proprietary network lowers unit costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Data Analytics and Clinical Protocols\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cphapvida uses centralized data from its proprietary network to enforce standardized clinical protocols that cut treatment variation and waste supporting a improvement in bed turnover reduction average cost per admission\u003e\n\u003cpby end-2025 investments in proprietary tech improved predictive models for patient risk and resource allocation driving a reported uplift early-intervention outreach helping contain the loss ratio versus peers.\u003e\n\u003cpthis data-driven approach identifies high-risk patients sooner reducing readmissions by and lowering claim severity which aided hapvida combined medical loss metrics in\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e6–8% better bed turnover (2024)\u003c\/li\u003e\n\u003cli\u003e4% lower cost per admission (2024)\u003c\/li\u003e\n\u003cli\u003e12% more early interventions (by end-2025)\u003c\/li\u003e\n\u003cli\u003e9% fewer readmissions (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pby\u003e\u003c\/phapvida\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated 400-hospital network: 14M beneficiaries, 18% EBITDA, 9% fewer readmissions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVertically integrated network of ~400 hospitals and 2,400 clinics drove ~62% owned-asset revenue in 2024, enabling ~18% adjusted EBITDA margin and ~6% cost-per-beneficiary savings (2023–24); ~14M beneficiaries end-2024 gives scale, strong procurement leverage, and regional dominance in North\/Northeast (~60% of assets), plus data-driven care cuts readmissions 9% and boosts early interventions 12% by end-2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOwned hospitals\/clinics\u003c\/td\u003e\n\u003ctd\u003e~400\/2,400 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeneficiaries\u003c\/td\u003e\n\u003ctd\u003e~14M (end-2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOwned-asset revenue\u003c\/td\u003e\n\u003ctd\u003e~62% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBITDA margin\u003c\/td\u003e\n\u003ctd\u003e~18% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost\/bene savings\u003c\/td\u003e\n\u003ctd\u003e~6% (2023–24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReadmissions drop\u003c\/td\u003e\n\u003ctd\u003e9% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEarly interventions\u003c\/td\u003e\n\u003ctd\u003e+12% (end-2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Hapvida’s internal strengths and weaknesses while outlining external opportunities and threats shaping its competitive position and growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise Hapvida SWOT snapshot for rapid strategic alignment and stakeholder-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Financial Leverage and Debt Servicing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe aggressive M\u0026amp;A push left Hapvida with net debt around BRL 9.8 billion as of 2024 year-end, forcing large cash outflows for interest and principal; interest expense consumed roughly 18% of 2024 operating profit. High Brazilian Selic rates averaging ~11.75% in 2024–2025 continued to depress net income, and the leverage profile restricts room for major capex or regular dividend increases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration Challenges Post-Merger\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe 2021 merger with NotreDame Intermédica created a complex structure; by Q3 2025 Hapvida (now Hapvida ND) still reported 18% of IT integrations incomplete and R$420m in one-time integration costs, slowing standardization of systems and culture.\u003c\/p\u003e\n\u003cp\u003eAnalysts expected synergies within 24 months, but operational redundancies persist: 6% higher administrative costs year-over-year through 2024 and delayed clinic network rationalization.\u003c\/p\u003e\n\u003cp\u003eThese integration hurdles have caused intermittent service-quality drops and longer wait times in some regions, raising beneficiary complaints by 14% in 2024—risking churn if fixes extend past 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustomer Service and Reputation Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHapvida has logged thousands of ANS (Brazilian National Supplementary Health Agency) complaints—ANS reported 3,412 service grievances in 2024—driven by long wait times and perceived care gaps at proprietary clinics, hurting Net Promoter Score and trust.\u003c\/p\u003e\n\u003cp\u003eNegative rankings and viral social-media complaints reduced bids won for large corporate TPA contracts in 2024, with reported corporate enrollment growth slowing to 2.1% vs 6.8% in 2022.\u003c\/p\u003e\n\u003cp\u003eManagement’s cost-cutting improved EBITDA margin to 10.7% in 2024, but patient satisfaction (ANS quality indicators) stayed below peers, showing the trade-off between efficiency and experience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSensitivity to Medical Loss Ratio Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDespite vertical integration, Hapvida remains highly sensitive to Medical Loss Ratio (MLR) swings; MLR rose to 83.2% in 2024 Q3, up from 79.6% year-over-year, squeezing EBITDA margins across its 12.8 million members.\u003c\/p\u003e\n\u003cp\u003eUnexpected spikes in elective procedures and a 2023 dengue surge increased claims, showing how seasonal outbreaks can quickly erode margins, especially in low-price segments with sub-5% operating margin buffers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMLR 2024 Q3: 83.2%\u003c\/li\u003e\n\u003cli\u003eMembers: 12.8M\u003c\/li\u003e\n\u003cli\u003eYOY MLR rise: +3.6 pp\u003c\/li\u003e\n\u003cli\u003eLow-price segment margin: \u0026lt;5%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration in Lower Income Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHapvida’s heavy reliance on C and D socio-economic classes (about 60% of 2024 enrolled lives) raises sensitivity to Brazil’s unemployment swings; when joblessness rose to 10.1% in Q4 2023 many low-income customers dropped private plans to cut costs.\u003c\/p\u003e\n\u003cp\u003eThis concentration means revenue and medical-loss ratios swing more than peers serving high-income clients, creating a cyclical risk profile tied to GDP and formal employment trends.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~60% lives in C\/D (2024 internal disclosure)\u003c\/li\u003e\n\u003cli\u003eBrazil unemployment 10.1% Q4 2023 — higher churn\u003c\/li\u003e\n\u003cli\u003eRevenue volatility \u0026gt; affluent-focused peers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh debt, rising costs and integration woes squeeze margins at major health plan\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh leverage (net debt BRL 9.8bn at 2024-year end) plus Selic ~11.75% cut net income and capex\/dividend flexibility; 18% of 2024 operating profit went to interest. Integration with NotreDame: 18% IT work incomplete, R$420m one-off costs, elevated admin costs (+6% YoY) and 14% rise in beneficiary complaints in 2024—MLR hit 83.2% (2024 Q3), members 12.8M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt (2024)\u003c\/td\u003e\n\u003ctd\u003eBRL 9.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelic (2024–25)\u003c\/td\u003e\n\u003ctd\u003e~11.75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMLR (2024 Q3)\u003c\/td\u003e\n\u003ctd\u003e83.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMembers\u003c\/td\u003e\n\u003ctd\u003e12.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eHapvida SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.\u003c\/p\u003e\n\u003cp\u003eThis is a real excerpt from the complete document. Once purchased, you’ll receive the full, editable version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752768844153,"sku":"hapvida-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/hapvida-swot-analysis.png?v=1772245173","url":"https:\/\/growthsharematrix.com\/products\/hapvida-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}